EGFR and non-small cell lung carcinoma: Although in NSCLC patients, personalized therapy was developed using not only using ALK gene but also EGFR as molecular target, the mechanisms of resistance between these two genes are completely distinct due to different tumor biology including genomic instability and different oncogenic dependency.